A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
News Abbott CEO: ‘We’re right on time’ to the PFA partyHealthradar15. Oktober 2025 By the numbers Q3 revenue: $11.37 billion 6.9% increase year over year Net income: $1.64 billion Flat year…
